Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study-Reference-Cited by-同舟云学术

Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study

Published:2014-03-02 Issue:5 Volume:92 Page:398-406
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Blommestein Hedwig M.¹,Issa Djamila E.²,Pompen Marjolein³⁴,Ten Hoor Gerhard³,Hogendoorn Mels⁵,Joosten Peter⁵,Zweegman Sonja²,Huijgens Peter C.²,Uyl-de Groot Carin A.¹

Affiliation:

1. Department of Health Policy & Management; Institute for Medical Technology Assessment; Erasmus University; Rotterdam The Netherlands

2. VU University Medical Center; Amsterdam The Netherlands

3. Roche Pharmaceuticals; Woerden The Netherlands

4. Currently employed at Bristol-Myers Squibb; Woerden The Netherlands

5. Medical Center Leeuwarden; Leeuwarden The Netherlands

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12264/fullpdf

Reference23 articles.

1. New treatment options have changed the survival of patients with follicular lymphoma;Fisher;J Clin Oncol,2005

2. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center;Liu;J Clin Oncol,2006

3. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford university experience;Tan;Blood,2013

4. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study;Salles;Blood,2008

5. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an east German study group hematology and oncology study;Herold;J Clin Oncol,2007

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Applying Trial-Derived Treatment Effects to Real-World Populations: Generalizing Cost-Effectiveness Estimates When Modeling Complex Hazards;Value in Health;2024-02

2. Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2021-05-02

3. Treatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma;Journal of Health Economics and Outcomes Research;2020-09-04

4. Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis;Cancer Medicine;2020-06-02

5. Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews;PharmacoEconomics - Open;2020-03-21